ProCE Banner Activity

KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer

Conference Coverage
Slideset

Health-related quality of life was maintained with the addition of pembrolizumab to gemcitabine and cisplatin in the phase III KEYNOTE-966 trial.

Released: June 06, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen